Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

Aging Male

Volumn 10, Issue 4, 2007, Pages 173-181

  Gooren, Louis J ^a   Behre, Hermann M ^b   Saad, Farid ^c   Frank, Annika ^c   Schwerdt, Sebastian ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Geographic difference; Phosphodiesterase inhibitor 5; Physician education; Prostate disease; Testosterone; Treatment decision

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; VARDENAFIL;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; ASIA; BRAZIL; CANCER RISK; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FEAR; GERMANY; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MARKET; MEDICAL RESEARCH; MOTIVATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; SAUDI ARABIA; SEXUAL FUNCTION; SOUTH KOREA; SPAIN; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE DEFICIENCY; TREATMENT DURATION; UNITED KINGDOM;

ADULT; ANDROGENS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HEALTH CARE SURVEYS; HUMANS; HYPOGONADISM; MALE; MARKETING; MEN'S HEALTH; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE; WORLD HEALTH;

EID: 36349036686     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530701600885     Document Type: Article

References (23)

1. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-876.
3. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56-58.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
5. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-2260.
6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
7. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-424.
8. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006;8:3-9.
9. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813-3817.
10. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006.
11. Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2006;86(5 Suppl):S236-240.
12. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? BJU Int 2004;94:1066-1070.
13. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006;91:2509-2513.
14. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®). World J Urol 2006;24:639-644.
15. Yassin AA, Saad F. Improvement of sexual functions in men with late onset hypogonadism treated with testosterone only. J Sex Med 2006;4:497-502.
16. Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006;27:165-175.
17. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-815.
18. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM, Torres LO. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004;1:69-81.
19. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-1041.
20. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-850.
21. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-250.
22. Jackson G. The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism. Eur Urol 2006;50:426-427.
23. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006;176:222-226.